Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 195,929 270,693 314,053 651,089
Total Sell Value $16,425,801 $23,384,210 $27,285,232 $61,044,052
Total People Sold 5 5 6 7
Total Sell Transactions 13 20 26 55
End Date 2024-03-03 2023-12-01 2023-06-02 2022-06-02

   
Records found: 2578
  Page 29 of 104  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-04-05 4 OE $14.39 $14,390 D/D 1,000 290,031     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2018-04-02 4 AS $80.12 $801,200 D/D (10,000) 156,676     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2018-04-02 4 OE $26.49 $337,851 D/D 10,000 163,326     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2018-04-02 4 AS $80.12 $169,774 D/D (2,119) 52,914     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-04-02 4 OE $14.39 $14,390 D/D 1,000 289,031     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2018-03-29 4 AS $79.69 $122,484 D/D (1,537) 55,033     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-03-28 4 OE $14.39 $32,250 D/D 2,000 288,031     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-03-27 4 OE $14.39 $14,390 D/D 1,000 286,031     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-03-26 4 OE $14.39 $14,390 D/D 1,000 285,031     -
   Davis George Eric EVP, General Counsel   •       –      –    2018-03-23 4 AS $81.35 $272,523 D/D (3,350) 87,989     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2018-03-22 4/A D $81.36 $474,736 D/D (5,835) 156,653     -
   Baffi Robert EVP, Technical Operations   •       –      –    2018-03-22 4/A D $81.36 $284,760 D/D (3,500) 84,445     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-03-22 4/A D $81.36 $1,068,013 D/D (13,127) 283,979     -
   Davis George Eric EVP, General Counsel   •       –      –    2018-03-22 4/A D $81.36 $269,139 D/D (3,308) 91,326     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2018-03-22 4/A D $81.36 $292,733 D/D (3,598) 56,555     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2018-03-22 4/A D $81.36 $292,733 D/D (3,598) 73,587     -
   Mueller Brian SVP, Corporate Controller   •       –      –    2018-03-22 4 D $81.36 $33,683 D/D (414) 17,559     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2018-03-22 4 D $81.36 $291,513 D/D (3,583) 73,602     -
   Davis George Eric EVP, General Counsel   •       –      –    2018-03-22 4 D $81.36 $268,081 D/D (3,295) 91,339     -
   Baffi Robert EVP, Technical Operations   •       –      –    2018-03-22 4 D $81.36 $283,621 D/D (3,486) 84,459     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2018-03-22 4 D $81.36 $291,513 D/D (3,583) 56,570     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2018-03-22 4 D $81.36 $472,864 D/D (5,812) 156,676     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-03-22 4 D $81.36 $1,063,782 D/D (13,075) 284,031     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-03-22 4 OE $14.39 $14,390 D/D 1,000 297,106     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2018-03-21 4 AS $83.90 $366,475 D/D (4,368) 60,153     -
  2578 Records found
  Previous  20  21  22  23  24  25  26  27  28  29  Next   
  Page 29 of 104
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us